GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
We will be circulating the amalgamated primary data set with iPSC Quality Round Participants next week. Thanks to Stem Cell Technologies, National Institute for Biological Standards and Controls (UK), Center for IPSC Research and Application (Kyoto University) & all Participants.
Bayer just bought Bluerock Tx showing a growing confidence in iPSC Therapy development
Bayer buys BlueRock in $600 million bet on stem cell therapies
By Ludwig Burger FRANKFURT (Reuters) – German drugmaker Bayer is paying up to $600 million (493.67 million pounds) for full control of cell therap...
Report from the ISCBI/GAiT/HSCI meeting held in Boston was just published in the latest issue of
(link: https://t.co/Hlp8nW2LLB) https://t.co/UP6ig54tPj
ISCT NA 2019 Plenary Spotlight: iPSC and Pluripotent Stem Cells - True Replacement Cell Therapies. Read more about this session at and register now https://t.co/IC72dsiGXg!
GAiT will speak at the 4th Annual Cell and Gene Therapy Symposium 5/6 September2019 at the Centre for Stem Cell Research, Vellore, India
GAiT will speak at Phaciliate Leaders World 17th - 18th SEPTEMBER 2019 in London
The agenda for this years conference has been designed to address the 3 core challenges presented by the European advanced therapies market: investmen...
The Promise and Price of Cellular Therapies by Siddhartha Mukherjee #celltherapy #genetherapy
The Promise and Price of Cellular Therapies
New “living drugs”—made from a patient’s own cells—can cure once incurable cancers. But can we afford them?
Update on the Quality Round will be issued later this week. We are currently clearing a backlog of GAiT internal administrative issues. Thanks for your patience.
The number of autologous products under clinical development is likely to cause a strain on #QC provision. Listen to this webinar on demand as Head of Quality Control Doli Patel considers some the challenges #webinar - https://t.co/orXn1sETRu